Association of MicroRNA-652 Expression with Radiation Response of Colorectal Cancer: A Study from Rectal Cancer Patients in a Swedish Trial of Preoperative Radiotherapy.
Surajit Pathak, Wen-Jian Meng, Sushmitha Sriramulu, Ganesan Jothimani, Jaganmohan Reddy Jangamreddy, Antara Banerjee, Alagu Theivanai Ganesan, Gunnar Adell, Xueli Zhang, Alexander Sun-Zhang, Hong Zhang, Xiao-Feng Sun
{"title":"Association of MicroRNA-652 Expression with Radiation Response of Colorectal Cancer: A Study from Rectal Cancer Patients in a Swedish Trial of Preoperative Radiotherapy.","authors":"Surajit Pathak, Wen-Jian Meng, Sushmitha Sriramulu, Ganesan Jothimani, Jaganmohan Reddy Jangamreddy, Antara Banerjee, Alagu Theivanai Ganesan, Gunnar Adell, Xueli Zhang, Alexander Sun-Zhang, Hong Zhang, Xiao-Feng Sun","doi":"10.2174/1566523223666230418111613","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Radiotherapy is a standard adjuvant therapy in patients with progressive rectal cancer, but many patients are resistant to radiotherapy, leading to poor prognosis. Our study identified <i>microRNA-652 (miR-652)</i> value on radiotherapy response and outcome in rectal cancer patients.</p><p><strong>Methods: </strong><i>miR-652</i> expression was determined by qPCR in primary rectal cancer from 48 patients with and 53 patients without radiotherapy. The association of <i>miR-652</i> with biological factors and the prognosis was examined. The biological function of <i>miR-652</i> was identified through TCGA and GEPIA database searches. Two human colon cancer cell lines (HCT116 p53<sup>+/+</sup> and p53<sup>-/-</sup>) were used for in vitro study. The molecular interactions of <i>miR-652</i> and tumor suppressor genes were studied through a computational approach.</p><p><strong>Results: </strong>In RT patients, <i>miR-652</i> expression was significantly decreased in cancers when compared to non-radiotherapy cases (<i>P</i> = 0.002). High <i>miR-652</i> expression in non-RT patients was with increased apoptosis marker (<i>P</i> = 0.036), ATM (<i>P</i> = 0.010), and DNp73 expression (<i>P</i> = 0.009). High <i>miR-652</i> expression was related to worse disease-free survival of non-radiotherapy patients, independent of gender, age, tumor stage, and differentiation (<i>P</i> = 0.028; HR = 7.398, 95% CI 0.217-3.786). The biological functional analysis further identified the prognostic value and potential relationship of <i>miR-652</i> with apoptosis in rectal cancer. <i>miR-652</i> expression in cancers was negatively related to WRAP53 expression (<i>P</i> = 0.022). After <i>miR-652</i> inhibition, the estimation of reactive oxygen species, caspase activity, and apoptosis in HCT116 p53<sup>+/+</sup> cells was significantly increased compared with HCT116 p53<sup>-/-</sup> cells after radiation. The results of the molecular docking analysis show that the miR652-CTNNBL1 and miR652-TP53 were highly stable.</p><p><strong>Conclusion: </strong>Our findings suggest the potential value of <i>miR-652</i> expression as a marker for the prediction of radiation response and clinical outcome in rectal cancer patients.</p>","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":" ","pages":"356-367"},"PeriodicalIF":3.8000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current gene therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1566523223666230418111613","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 1
Abstract
Background: Radiotherapy is a standard adjuvant therapy in patients with progressive rectal cancer, but many patients are resistant to radiotherapy, leading to poor prognosis. Our study identified microRNA-652 (miR-652) value on radiotherapy response and outcome in rectal cancer patients.
Methods: miR-652 expression was determined by qPCR in primary rectal cancer from 48 patients with and 53 patients without radiotherapy. The association of miR-652 with biological factors and the prognosis was examined. The biological function of miR-652 was identified through TCGA and GEPIA database searches. Two human colon cancer cell lines (HCT116 p53+/+ and p53-/-) were used for in vitro study. The molecular interactions of miR-652 and tumor suppressor genes were studied through a computational approach.
Results: In RT patients, miR-652 expression was significantly decreased in cancers when compared to non-radiotherapy cases (P = 0.002). High miR-652 expression in non-RT patients was with increased apoptosis marker (P = 0.036), ATM (P = 0.010), and DNp73 expression (P = 0.009). High miR-652 expression was related to worse disease-free survival of non-radiotherapy patients, independent of gender, age, tumor stage, and differentiation (P = 0.028; HR = 7.398, 95% CI 0.217-3.786). The biological functional analysis further identified the prognostic value and potential relationship of miR-652 with apoptosis in rectal cancer. miR-652 expression in cancers was negatively related to WRAP53 expression (P = 0.022). After miR-652 inhibition, the estimation of reactive oxygen species, caspase activity, and apoptosis in HCT116 p53+/+ cells was significantly increased compared with HCT116 p53-/- cells after radiation. The results of the molecular docking analysis show that the miR652-CTNNBL1 and miR652-TP53 were highly stable.
Conclusion: Our findings suggest the potential value of miR-652 expression as a marker for the prediction of radiation response and clinical outcome in rectal cancer patients.
期刊介绍：
Current Gene Therapy is a bi-monthly peer-reviewed journal aimed at academic and industrial scientists with an interest in major topics concerning basic research and clinical applications of gene and cell therapy of diseases. Cell therapy manuscripts can also include application in diseases when cells have been genetically modified. Current Gene Therapy publishes full-length/mini reviews and original research on the latest developments in gene transfer and gene expression analysis, vector development, cellular genetic engineering, animal models and human clinical applications of gene and cell therapy for the treatment of diseases.
Current Gene Therapy publishes reviews and original research containing experimental data on gene and cell therapy. The journal also includes manuscripts on technological advances, ethical and regulatory considerations of gene and cell therapy. Reviews should provide the reader with a comprehensive assessment of any area of experimental biology applied to molecular medicine that is not only of significance within a particular field of gene therapy and cell therapy but also of interest to investigators in other fields. Authors are encouraged to provide their own assessment and vision for future advances. Reviews are also welcome on late breaking discoveries on which substantial literature has not yet been amassed. Such reviews provide a forum for sharply focused topics of recent experimental investigations in gene therapy primarily to make these results accessible to both clinical and basic researchers. Manuscripts containing experimental data should be original data, not previously published.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
